ArticleBritish journal of cancer2017
PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype.
Article in British journal of cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Joint EANM-SNMMI guideline on the role of 2-[European journal of nuclear medicine and molecular imaging · 2024Guideline
- Diffusion-Weighted MRI for the Assessment of Molecular Prognostic Biomarkers in Breast Cancer.Korean journal of radiology · 2024Pooled it
- Positron-emission tomography as a predictor of response to first-line cyclin-dependent kinase 4/6 inhibitors in patients with metastatic ER-positive HER2-negative breast cancer.NPJ breast cancer · 2026Article
- Hybrid [Bioengineering (Basel, Switzerland) · 2026Article
- Comparison of MR cytometry methods in predicting immunohistochemical factor status and molecular subtypes of breast cancer.Radiology and oncology · 2025Article
- Microstructural diffusion MRI for differentiation of breast tumors and prediction of prognostic factors in breast cancer.Frontiers in oncology · 2025Article
- Prediction of therapy response of breast cancer patients with machine learning based on clinical data and imaging data derived from breast [European journal of nuclear medicine and molecular imaging · 2024Article
- Three-Dimensional In Vitro Tumor Spheroid Models for Evaluation of Anticancer Therapy: Recent Updates.Cancers · 2023Review
- Towards a fast PET/MRI protocol for breast cancer imaging: maintaining diagnostic confidence while reducing PET and MRI acquisition times.European radiology · 2023Article
- Article
- Simultaneous multislice diffusion-weighted imaging versus standard diffusion-weighted imaging in whole-body PET/MRI.European radiology · 2023Article
- Correlation between Imaging Markers Derived from PET/MRI and Invasive Acquired Biomarkers in Newly Diagnosed Breast Cancer.Cancers · 2023Article
- Breast PET/MRI Hybrid Imaging and Targeted Tracers.Journal of magnetic resonance imaging : JMRI · 2023Review
- The influence of receptor expression and clinical subtypes on baseline [18F]FDG uptake in breast cancer: systematic review and meta-analysis.EJNMMI research · 2023Review
- Added value of quantitative, multiparametric 18F-FDG PET/MRI in the locoregional staging of rectal cancer.European journal of nuclear medicine and molecular imaging · 2022Article
- Breast Cancer Subtypes and Quantitative Magnetic Resonance Imaging: A Systemic Review.Life (Basel, Switzerland) · 2022Review
- Proof of concept of a multimodal intravital molecular imaging system for tumour transpathology investigation.European journal of nuclear medicine and molecular imaging · 2022Article
- PET/MRI and PET/CT Radiomics in Primary Cervical Cancer: A Pilot Study on the Correlation of Pelvic PET, MRI, and CT Derived Image Features.Molecular imaging and biology · 2022Article
- Preliminary experiences of PET/MRI in predicting complete response in patients with breast cancer treated with neoadjuvant chemotherapy.Molecular and clinical oncology · 2022Article
- Clinical advances in PET-MRI for breast cancer.The Lancet. Oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDifferences in genetics and receptor expression (phenotypes) of invasive ductal breast cancer (IDC) impact on prognosis and treatment response. Immunohistochemistry (IHC), the most used technique for IDC phenotyping, has some limitations including its invasiveness. We explored the possibility of contrast-enhanced positron emission tomography magnetic resonance (CE-FDG PET/MR) to discriminate IDC phenotypes.
methods21 IDC patients with IHC assessment of oestrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor-2 (HER2), and antigen Ki-67 (Ki67) underwent CE-FDG PET/MR. Magnetic resonance-perfusion biomarkers, apparent diffusion coefficient (ADC), and standard uptake value (SUV) were compared with IHC markers and phenotypes, using a Student's t-test and one-way ANOVA.
resultsER/PR- tumours demonstrated higher Kep
conclusionsPositron emission tomography magnetic resonance might non-invasively help discriminate IDC phenotypes, helping to optimise individual therapy options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.